Ananda Pharma PLC - Appointment of Giles Moss as Advisor

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 6^th May 2025

ANANDA PHARMA PLC 

("Ananda" or the "Company") 

Appointment of Giles Moss, ex-Senior GW Pharmaceuticals' Executive, as Advisor

Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF), a UK-based biopharmaceutical company developing regulatory approved cannabinoid medicines to treat complex, chronic conditions, is pleased to announce the appointment of Mr. Giles Moss, ex- senior executive at GW Pharmaceuticals plc ("GW") as an Advisor.

Highlights

·    GW achieved the first ever regulatory approval for a naturally derived cannabidiol medicine in the US, UK and Europe

·    Mr Moss was GW's General Manager of Europe when it was acquired by Jazz Pharmaceuticals for $7.2bn, globally the largest strategic cannabis exit to date

·    Mr Moss was a key GW executive who led the operational growth of the company, including commercial infrastructure build, staffing expansion, country launchs of Epidyolex as well as government and public affairs

·    To view the supporting video and ask questions please go to our Hub: https://investors.anandapharma.co.uk/link/Ve9KVP

Giles Moss was a key member of the leadership team at GW Pharmaceuticals plc, the world's first company to successfully pursue and receive FDA approval for a cannabidiol ("CBD") based pharmaceutical. Mr. Moss joined GW in 2016 as Head of International Operations, Government and Public Affairs, and was responsible for building out GW's operations outside the UK and USA. He remained at GW until it was acquired by Jazz Pharmaceuticals for $7.2 billion in 2021, the largest strategic exit transaction in the cannabinoid industry to date.

Mr. Moss will help guide the Ananda team with advice on the technical and regulatory aspects of drug licencing and strategy, and in financing and capital markets. Additionally, he will work closely with the Ananda Board to build out its best-in-class team to deliver its own regulatory approved CBD drug to market. Securing Mr. Moss' services allows Ananda to benefit from his unique experience in building a business around a a regulatory approved CBD drug and as with Chris Tovey, whose appointment as Advisor was announced on 8 April, it is intended that Mr Moss will join the Board in due course. To align his interests with shareholders, a total of 30,000,000 options have been granted for ordinary shares of £0.002 each in the capital of the Company ("Ordinary Shares") to Mr Moss, subject to certain vesting and performance conditions, all with a 10-year life. The options have an exercise price of 0.41 pence, being the 7-day VWAP preceeding his appointment as a consultant. Conditional upon being appointed a director of the Company, Mr. Moss would be granted options over up to a further 45,000,000 Ordinary Shares with an exercise price of the 7-day VWAP preceeding his appointment to the Board of Ananda.

Ananda's CEO, Melissa Sturgess commented: "We are honoured to have Giles join us.  His input will help us achieve our ambition of getting a regulatory approved CBD drug to market faster and at a lower cost than would otherwise be the case.  His senior level experience at GW will be invaluable and his commitment to Ananda is a vote of confidence in our approach and our team. We have now recruited two ex-GW leaders to our team, both are on track to increasing their roles and their remuneration is aligned with shareholders' interests - we take all three points as significant endorsements of Ananda's strategy and outlook."

Giles Moss added: "There remains genuine unfinished business in the cannabinoid space due to the very limited therapeutic access to potentially life changing medicines. Demand from both physicians and patients for regulatory approved CBD therapeutics continues. The time is ripe to lead the way in developing the next generation of cannabis derived, regulatory approved medicines and I am very much looking forward to supporting Ananda on the journey."

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

To stay up to date with the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

-Ends-  

For the purposes of UK MAR, the Directors of the Company accept responsibility for the contents of this announcement.